Meiji Seika Pharma and Foundation for Biomedical Research and Innovation begin phase I trial of ME3241 to evaluate safety & tolerability in Australia: Tokyo Saturday, March 14, 20 ...
The positions in the table below reflect the Foundation for Biomedical Research and Innovation (FBRI)'s position overall, domestically, within their sector, and in various subject areas based on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results